Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection.

Trial Profile

Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Mupirocin (Primary)
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Acronyms NOSE
  • Most Recent Events

    • 07 Jan 2009 Primary endpoint 'Bacteriological colonisation rate' has been met.
    • 09 Dec 2008 New trial record.
    • 28 Oct 2008 Results have been presented at the 2008 ICAAC/IDSA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top